Skip to content Skip to footer
Subscribe Now
GSK
News

GSK Receives the CHMP’s Positive Opinion for Blenrep (Belantamab Mafodotin) Regimens to Treat R/R Multiple Myeloma

SShots:CHMP recommended Blenrep + BorDex & PomDex in MM pts with ≥1 prior therapy; EC decision expected in Q3’25. Review ongoing in the US (PDUFA: Jul 23, 2025), Canada, China (PR for DREAMM-7), & Switzerland (PR for DREAMM-8)Opinion was based on P-III (DREAMM-7 & DREAMM-8) trials assessing Blenrep + BorDex vs Darzalex + BorDex in 494…
4 days ago

Read more

Viewpoints_Yelak Biru
VIEWPOINTS

Fund Raising Initiative: Yelak Biru from International Myeloma Foundation in Conversation with PharmaShots

Shots:  As a fund-raising initiative, the International Myeloma Foundation began a 3-day, 2-night cycling expedition from Aug 29thto Sep 3rd The initiative supports patient education, advocacy, and next-gen research to advance a cure for multiple myeloma Today, at PharmaShots we have Yelak Biru, President and CEO of the International Myeloma Foundation, shedding light on this…
October 16, 2024

Read more

Exclusive_Chris Heery_2024
EXCLUSIVE

Advancing Care for Hematologic Malignancies: Chris Heery from Arcellx in a Stimulating Dialogue Exchange with PharmaShots

Shots: Arcellx’s Anito-cel, a BCMA CAR-T therapy recently got the FTD, ODD, RMAT designations by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (r/rMM) Today, at PharmaShots we have Chris Heery, Chief Medical Officer at Arcellx, shedding light on Anito-Cel therapy in advancing care for multiple myeloma In late 2022,…
September 30, 2024

Read more

Viewpoints_Dr. Robert Rifikin
VIEWPOINTS

Establishing Safe Treatment: Dr. Robert Rifikin from Rocky Mountain Cancer Centers in Conversation with PharmaShots

Shots: There is an average lifetime risk of getting multiple myeloma of about 1 in 103 men and 1 in 131 women in the United States Treatment of multiple myeloma using fourth-line therapy like teclistamab can induce issues like cytokine release syndrome (CRS) and neurotoxicity  Today, at PharmaShots we have Dr. Robert Rifikin from Rocky…
August 5, 2024

Read more

New Drug Designations - August 2023
INSIGHTS+

New Drug Designations – August 2023

Shots: PharmaShots' designation report provides a concise overview of several drugs and their designations by the US FDA, the EU, Japan, and China. This month’s report includes 8 biological drugs, 13 small molecules, 4 cell and gene therapies, 3 diagnostic tests and 5 devices Genprex’ Reqorsa, focused on the treatment of SCLC, is the drug to receive ODD…
September 18, 2023

Read more

Load more

Sign Up to Our Newsletter

Be the first to know the latest updates

[mc4wp_form id="13387" element_id="style-1"]